Dr Soo Yei HO is Chief of Staff at EDDC, where she collaborates with the CEO in setting and managing the company’s overall strategy for people and operations. Her role involves translating the operation and hiring strategy into actionable steps, implementing organization-wide goal setting, performance management, and annual operations planning. She also manages the resources within the organization in the areas of budget, portfolio, and personnel. Additionally, she assumes the role of overseeing the daily operations at EDDC.

Before assuming her current position, Soo Yei held the position of Acting Director of Discovery Chemistry, where her responsibilities included overseeing medicinal chemistry activities and establishing chemical biology capabilities. She was previously Associate Director of Project Management at EDDC, where she led the Project Management Office and oversaw EDDC’s portfolio of projects and platforms.

Soo Yei joined the Experimental Therapeutics Centre in 2011, where she rose through the ranks to become a Group Leader (Medicinal Chemistry). During her tenure, she worked on several small molecule drug discovery projects in the areas of oncology and anti-infectives. She is the inventor of ETC-159, Singapore’s first publicly funded drug, which is currently in Phase 1B clinical trial. For her outstanding contributions to the Wnt-porcupine project, she received the A*STAR Borders Award in 2016. Soo Yei holds more than 20 composition-matter patents and has published many research papers in the field of medicinal chemistry.

Before joining A*STAR, Soo Yei worked as a Research Scientist at two US Biotech companies, FORMA Therapeutics Inc. (2008-2011) and Infinity Pharmaceuticals (2005-2007).

Soo Yei obtained her Ph.D. from the Department of Chemistry at the National University of Singapore.